GSK PLC SEC Filings

GSK plc reported the results of its 26th hybrid Annual General Meeting, where shareholders could participate in person or online. All 25 resolutions were passed on a poll, including the receipt and adoption of the 2025 Annual Report and approval of the annual remuneration report and policy.

Support for the 2025 Annual Report reached 3,073,839,952 votes in favour, or 99.25% of votes cast, with total votes on that resolution representing 76.38% of issued share capital. All directors standing for election or re-election were backed by large majorities, and the auditor’s re-appointment and remuneration were also strongly approved.

Shareholders granted authorities to allot shares, disapply pre-emption rights, and purchase the company’s own shares, with each relevant special resolution receiving well over the required 75% majority. Overall AGM participation, including votes cast and withheld, represented 76.59% of GSK’s issued share capital excluding treasury shares.

FMR LLC reported beneficial ownership of $0 234,936,060.81 shares of GSK PLC common stock, representing 5.8% of the class as disclosed for the period ending 03/31/2026. The filing lists sole voting power of 171,486,572.69 shares and sole dispositive power of 234,936,060.81 shares. The schedule notes that one or more other persons may have rights to dividends or sale proceeds and refers to Exhibit 99 and an attached power of attorney.

GSK plc granted a deferred investment award to new Chief People Officer and Executive Committee member Roanne Parry. The award is over notional Ordinary Shares, referenced to 35,507.628 shares at a price of £19.01 per share, and is intended to align long term with shareholders.

The award vests in two stages, with 34.22% scheduled to vest on 31 August 2028 and 65.78% on 31 August 2029, provided Ms Parry has not resigned or been terminated for cause. Dividends will accrue during the vesting period, and the benefit will be settled in cash on vesting.

GSK plc reported its share capital and voting rights as of 30 April 2026. The company had 4,316,202,660 ordinary shares of 31¼ pence each in issue, including 261,378,286 shares held in treasury. This leaves a total of 4,054,824,374 voting rights for shareholder disclosure calculations.

GSK plc files a Form 6-K reporting a TR-1 notification that a major holder has 4.930000% of its voting rights, representing 200,296,898 voting rights in total. These are held through ordinary shares and ADRs, with no additional voting rights linked to financial instruments.

The filing shows 88,958,040 voting rights (2.190000%) attached to ordinary shares and 111,338,858 voting rights (2.740000%) through ADRs, together making up the reported 4.930000% position.

GSK plc reported two senior personnel share transactions. Independent Non-Executive Director Wendy Becker purchased 4,000 Ordinary Shares at £19.6291 each on the London Stock Exchange on 2026-04-29. Ordinary Shares have a nominal value of 31¼ pence.

Chief People Officer Diana Conrad acquired 12.874 American Depositary Shares at $54.5854 per ADS under the GSK pension plan on the New York Stock Exchange on 2026-04-27. Both transactions are disclosed as initial notifications of dealings by persons discharging managerial responsibilities.

GSK reported Q1 2026 results showing steady growth driven by Specialty Medicines. Turnover reached £7.6 billion, up 5% at constant exchange rates (CER), with Specialty Medicines up 14% CER to £3.2 billion, led by HIV, respiratory and oncology products.

Core operating profit rose 10% CER to £2.65 billion, with core EPS up 9% CER to 46.5p, helped by a richer product mix, lower SG&A and higher royalty income, partly offset by increased R&D. Free cash flow was £815 million, while net debt increased to £15.6 billion following acquisitions, dividends and buybacks.

GSK declared a 17p Q1 dividend and expects a 70p dividend for 2026. The company affirmed 2026 guidance of 3–5% turnover growth and 7–9% growth in both core operating profit and core EPS at CER, and reiterated a 2031 sales outlook of more than £40 billion. GSK also highlighted multiple new product approvals, a broad late‑stage pipeline and a US agreement providing Section 232 tariff relief on patented medicines through 20 January 2029.

GSK plc reports the vesting of a 2023 Performance Share Plan award granted to its Chief Financial Officer, Julie Brown. Following performance assessment, 82% of this award vested and 18% lapsed.

The vesting delivered 243,880 Ordinary Shares at a price of £0.00 per share, including dividend equivalents, on 27 April 2026. These vested shares are subject to an additional two-year holding period. The closing price of GSK Ordinary Shares on the vesting date was £20.16.

GSK reports that the US FDA has accepted for priority review a New Drug Application for bepirovirsen, an investigational antisense oligonucleotide for adults with chronic hepatitis B. The FDA has also granted Breakthrough Therapy Designation, adding to the Fast Track Designation awarded in February 2024.

The submission is backed by phase III B-Well 1 and B-Well 2 trials, where bepirovirsen plus standard of care achieved statistically significant, clinically meaningful functional cure rates versus standard of care alone, with an acceptable safety profile. Chronic hepatitis B affects more than 250 million people worldwide, and current standard therapies usually require lifelong treatment with low functional cure rates around 1%. The FDA has assigned 26 October 2026 as the PDUFA goal date.